GSK (NYSE:GSK) Rating Increased to Strong-Buy at StockNews.com

GSK (NYSE:GSK) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and decreased their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Performance

NYSE GSK opened at $32.12 on Monday. The firm’s 50 day simple moving average is $34.20 and its 200 day simple moving average is $38.08. The firm has a market capitalization of $66.57 billion, a price-to-earnings ratio of 20.86, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK has a 1 year low of $31.72 and a 1 year high of $45.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Eastern Bank bought a new stake in GSK in the third quarter worth approximately $26,000. ST Germain D J Co. Inc. increased its stake in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares in the last quarter. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares in the last quarter. Concord Wealth Partners lifted its position in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares during the period. Finally, Ashton Thomas Private Wealth LLC bought a new position in GSK during the second quarter worth $37,000. 15.74% of the stock is owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.